Axsome Settles Investors' Drug Approval Suit For $7.8M

By Sydney Price · September 23, 2025, 8:23 PM EDT

Biopharmaceutical company Axsome Therapeutics Inc. and its shareholders have asked a New York federal court to approve a $7.75 million settlement to resolve investors' claims that Axsome hid issues related to...

To view the full article, register now.

Documents

Case Information

Case Title

In re Axsome Therapeutics, Inc. Securities Litigation

Case Number

1:22-cv-03925

Court

New York Southern

Nature of Suit

Securities/Commodities

Date Filed

May 13, 2022